Skip to content

ALZN

Alzamend Neuro, Inc.

NASDAQ · Healthcare · Biotechnology · US

$1.89
+2.72%
Ask drillr

Income statement

MetricTTM2026202520242023
Revenue
Total Revenue
Cost of Revenue55.4K
Gross Profit(55.4K)
Operating Expenses
R&D Expense3.0M3.6M1.4M6.5M7.4M
SG&A Expense6.1M5.1M3.1M3.5M7.4M
General & Admin Expense6.3M5.1M2.7M3.2M6.7M
Selling & Marketing Expense(150.0K)347.3K247.3K742.6K
Other Expenses(55.4K)
Total Operating Expenses9.0M8.8M4.5M9.9M14.9M
Cost and Expenses9.1M8.8M4.5M9.9M14.9M
Operating Income (EBIT)(9.1M)(8.8M)(4.5M)(9.9M)(14.9M)
Non-Operating
Interest Income1.5K1.1K
Interest Expense(11.1K)(6.6K)18.0K10.1K7.7K
Net Interest Income8.6K7.7K(18.0K)(10.1K)(7.7K)
Other Non-Op Income/Expense(4.7K)(5.5K)(18.0K)(10.1K)(7.7K)
Non-Operating Income (excl Interest)(1.1K)
EBT (Pre-Tax Income)(9.1M)(8.8M)(4.5M)(9.9M)(14.9M)
Income Tax Expense
Bottom Line
Net Income(9.1M)(8.8M)(4.5M)(9.9M)(14.9M)
Earnings from Cont. Ops(9.1M)(8.8M)(4.5M)(9.9M)(14.9M)
Earnings from Discont. Ops
Bottom Line Net Income(9.1M)(8.8M)(5.1M)(9.9M)(14.9M)
Per Share
Basic EPS($2.30)($2.63)($11.32)($132.33)($205.97)
Diluted EPS($2.30)($2.63)($11.32)($132.33)($205.97)
Revenue Per Share$0.00$0.00$0.00$0.00$0.00
Shares
Basic Shares Outstanding4.5M3.3M3980007500072000
Diluted Shares Outstanding4.5M3.3M4507997517472236
Profitability Metrics
EBITDA(9.1M)(8.7M)(4.4M)(9.9M)(14.8M)
D&A110.7K50.7K50.7K23.1K
EBIT(9.1M)(8.8M)(4.5M)(9.9M)(14.9M)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jul 1, 2026